Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Retrophin to Report First Quarter 2017 Financial Results


Posted on: 20 Apr 17

SAN DIEGO, April 20, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq:RTRX) today announced it will report first quarter 2017 financial results on Thursday, May 4, 2017 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.            

 
Conference Call Information
  
Date:Thursday, May 4, 2017
Time:4:30 p.m. ET
Dial-in numbers:+1 (855) 219-9219 (U.S.) or +1 (315) 625-6891 (International)
Confirmation code:10209780
Live webcast:www.retrophin.com in the "Events & Presentations" section of the "Investors" page
  

A replay of the call will be available from 7:30 p.m. ET, May 4, 2017 to 7:30 p.m. ET, May 11, 2017. The replay number is +1 (855) 859-2056 (U.S.) or +1 (404) 537-3406 (International), confirmation code 10209780.

About Retrophin

Retrophin is a fully integrated biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options. The Company's approach centers on its pipeline featuring late-stage candidates targeting rare diseases with significant unmet medical needs, including sparsentan for focal segmental glomerulosclerosis (FSGS), a disorder characterized by progressive scarring of the kidney often leading to end-stage renal disease, and RE-024 for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood. Research exploring the potential of early-stage assets in several rare diseases is also underway. Retrophin's R&D efforts are supported by revenues from the Company's commercial products, Thiola®, Cholbam®, and Chenodal®.

Retrophin.com

GlobeNewswire
globenewswire.com

Last updated on: 22/04/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.